Compare CVAC & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVAC | OCSL |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2020 | 2008 |
| Metric | CVAC | OCSL |
|---|---|---|
| Price | $5.12 | $13.65 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 3 |
| Target Price | $6.83 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 1.7M | 596.7K |
| Earning Date | 11-24-2025 | 11-18-2025 |
| Dividend Yield | N/A | ★ 11.72% |
| EPS Growth | ★ 94.02 | N/A |
| EPS | ★ 0.94 | 0.39 |
| Revenue | $83,000,117.00 | ★ $316,801,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.40 | N/A |
| P/E Ratio | ★ $5.47 | $34.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.48 | $12.44 |
| 52 Week High | $5.72 | $16.50 |
| Indicator | CVAC | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 51.50 |
| Support Level | $5.11 | $13.51 |
| Resistance Level | $5.23 | $13.76 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 30.83 | 68.38 |
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.